Skip to main content
Premium Trial:

Request an Annual Quote

NHLBI Starts $76M Genetic Variation Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Heart, Lung, and Blood Institute plans to pump $76 million over the next five years into a program aimed at combining cellular tools, molecular profiling, and genomics to study human genomic variation and genetic links to disease.

The "Next Generation Genetic Association Studies" program will support between five and eight grants to researchers that aim to combine cellular reprogramming strategies, molecular profiling, and cellular assays, and integrate them into existing genotypic and clinical phenotypic data on naturally occurring human genetic variation.

Under the program, NHLBI will provide up to $5.8 million in total direct costs for each applicant, including up to $500,000 in first-year costs, second-year costs of up to $825,000, and the third through fifth-year costs are not to exceed $1.5 million.

Applicants for funding may propose phases I to III or II to III, depending on the current state of iPS generation and cell type differentiation technology needed to meet their specific aims, the institute said.

The first-phase grants will support one technology development phase aimed at using emerging induced pluripotent stem cell generation and differentiation technologies to generate cell types relevant to heart, lung, and blood diseases, and the second phase will involve scaling up the technology.

The third phase of the grants will support integrating cellular reprogramming, molecular profiling, physiological or biochemical assays, and existing genotype and phenotype information to assess the functional significance of human genetic variation.

"The resulting data will allow assessment of how human genetic variation influences the activities of biological networks in cell-based models of disease," NHLBI explained in the funding request.

"Addressing this goal will require a multidisciplinary approach, consisting of teams including, but not limited to, epidemiologists, clinicians, population geneticists, stem cell and molecular biologists, and bioinformaticians," said NHBLI.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.